6:04 PM
 | 
Dec 23, 2008
 |  BC Extra  |  Company News

GSK passes on Cytokinetics options

GlaxoSmithKline (LSE:GSK;NYSE:GSK) said it will not exercise its option to license ispinesib and SB-743921 from Cytokinetics (NASDAQ:CYTK) under a 2001 deal. GSK said the decision not to license the kinesin spindle protein ( KSP) inhibitors was...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >